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We report a novel long-lived infection model in human mixed glial cultures (microglia) whereby cells harbor replication-competent HIV-1
for up to 2.5 months after infection; a model that potentially mimics latency within the central nervous system (CNS). Infection of mixed glial
cultures in the presence of serum, cytokines, and growth factors (activating conditions) resulted in a robust productive infection of microglial
cells as previously described for purified microglia. In contrast, similar mixed glial cells cultured in serum-free medium without cytokines or
growth factors (mirroring a nonactivated CNS) supported HIV-1 entry, reverse transcription, integration, and transcription, yet released little
or no infectious virus. We found instead that nonactivated mixed glial cells expressed almost 10-fold less Gag protein, but more importantly,
analysis of the intracellular Gag products in quiescent cells showed an aberrant p55/p24 Gag processing phenotype that appeared to be due to
the premature activity of the viral protease. These results suggest that the cellular environment in nonactivated microglia cells in these mixed
glial cultures is not conducive to proper Gag processing and virus release. This long-lived infection model will be useful in identifying factors
that are key for viral maturation in cells of the macrophage lineage.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV replication; Glial cultures; p55Gag; Microglia
Introduction HAART’s efficacy in reducing plasma viral load alsoHighly active anti-retroviral therapy (HAART) has had a
dramatic effect on systemic HIV replication with a conse-
quent reduction in the overall morbidity and mortality of
infected persons (Gulick et al., 1997; Hammer et al., 1997;
Palella et al., 1998). Widespread use of HAART has also
reduced the number of new cases of HIV-associated demen-
tia (HAD), an important HIV complication in the central
nervous system (CNS). Still, HIV-associated cognitive im-
pairment continues to be a major clinical problem, in part
due to the increased life span of HIV-infected individuals,
and additionally because of a recently described less severe
form of the disease (Dore et al., 1999; Neuenburg et al.,
2002; Sacktor et al., 2002).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.028
$ Supplementary data associated with this article can be found, in the
online version, at doi:10.1016/j.virol.2004.04.028.
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E-mail address: scarano@mail.med.upenn.edu (F. Gonza´lez-Scarano).facilitated detailed studies of the viral decay kinetics in
infected individuals (Ho et al., 1995; Perelson et al., 1996,
1997; Wei et al., 1995); these studies uncovered the exis-
tence of multiple pools of infected cells, including some
long-lived viral reservoirs. Among these, CD4+ T lympho-
cytes (T cells), which when activated are responsible for
producing the majority of the infectious virus in the blood-
stream, can also support a latent or slowly productive
infection (Chun et al., 1995). Resting memory CD4+ T
cells, responsible for this slow phase of the infection, are
estimated to have a half-life of 6–44 months (Pierson et al.,
2000), making complete eradication of the virus with
current therapies difficult or unlikely (Demoustier et al.,
2002). However, this cell type probably does not entirely
account for HIV persistence (Chun et al., 1995, 1997a,
1997b; Perelson et al., 1997). Other potential reservoirs
include lymph nodes, CNSmicroglia andmacrophages, other
tissue macrophages, gut lymphoid tissue, rectal mucosa, the
urogenital tract, and HIV held in the follicular dendritic cell
(FDC) network (Cavert and Haase, 1998; Cavert et al., 1997;
Chun et al., 1997a, 1997b; Crowe and Sonza, 2000; Kedzier-
A.V. Albright et al. / Virology 325 (2004) 328–339 329ska and Crowe, 2002; Lebargy et al., 1994; McIlroy et al.,
1996; Mikovits et al., 1992; Persaud et al., 2000; Pomerantz,
2002; Schrager and D’Souza, 1998; Sierra-Madero et al.,
1994; Sonza et al., 2001; van Furth, 1989).
There are known major blocks to HIV replication at two
key points in the viral life cycle: after reverse transcription
but before integration (pre-integration latency), and after the
provirus has been incorporated into the host cell genome
(post-integration latency) (Blankson et al., 2000). Pre-inte-
gration latency appears to be more common, but is limited
by the half-life of the labile pre-integration complex, which
is generally measured in days (Pierson et al., 2002). In post-
integration latency, which may last for the lifetime of the
infected memory T cell, the provirus is integrated into the
host cell genome but remains transcriptionally silent (Jordan
et al., 1991; Persaud et al., 2000). Based on in vitro models,
several mechanisms have been proposed for post-integra-
tion latency, including reduced levels of transcriptional
activators in resting cells and integration into silent regions
of the host genome (Butera, 2000; Jordan et al., 2003;
Kutsch et al., 2002; Quivy and Van Lint, 2002). Current
models would propose that upon cellular activation, tran-
scription factors that are key to HIV replication are upregu-
lated and viral replication resumes. Nevertheless, there are
likely to be important cell type differences in the HIV-
specific transcription factors between T lymphocytes and
macrophages (Kutsch et al., 2002; Roberts et al., 1997).
Other than their mostly theoretical contribution to viral
reservoirs, little is known regarding the specific role of
chronically infected macrophages (Butera, 2000; Kutsch et
al., 2002; Laurence, 1993; Meltzer et al., 1990; Pierson et al.,
2000; Roy and Wainberg, 1988). While recent reports
indicate that cellular activation and reactivation of HIV
replication can be uncoupled in latently infected T lympho-
cytes (Kutsch et al., 2002), macrophages have not been
studied as intensively. In this regard, microglia and other
CNS macrophages may serve as replication competent HIV
reservoirs, because some retroviral drugs have poor CNS
penetration and a T lymphocyte immune response in the
CNS is both limited and to some extent undesirable (De Luca
et al., 2002). Additionally, HIV-infected monocytes from
outside the CNS may constitutively seed the brain and return
to the periphery in the normal process of trafficking of
immune cells in and out of the nervous system (Lawson et
al., 1992; Vass et al., 1993). Technologies used to study the
occurrence of HIV latency in primary resting T cell popula-
tions in vitro (Chun et al., 1995) have not been adapted to
terminally differentiated tissue macrophages; therefore, there
are no commonly used in vitro models to study viral
persistence in macrophages.
To develop a model to address some of these questions,
we adapted a well-characterized microglial culture system
that we have used previously for studies of HIV replication
in the CNS (Albright et al., 1999; Strizki et al., 1996). When
cultured in a mixed culture system with astrocytes and
oligodendroglia, the microglia survived for weeks absentexogenous growth factors or even supplemental fetal calf
serum (FCS) (Albright et al., 2000b). Under these medium
conditions, which mirror a nonactivated CNS milieu, the
cells were easily infected, but had a markedly reduced level
of infectious virion production and release that could be
restored by adding serum components, growth factors, and
cytokines. We compared low-level HIV infection in non-
activating culture conditions with replication in activated
cultures using assays for reverse transcription, integration,
transcription, and protein expression. We conclude there are
multiple levels of restriction of viral replication in the
nonactivated microglia model with the greatest restriction
apparently at a posttranscriptional level. The restriction was
also associated with an alteration in the processing of
p55Gag. Our results may help identify host factors involved
in viral persistence in macrophages.Results
HIV infection in nonactivating and activating medium
conditions
We cultured mixed glial cells isolated from fresh human
adult brain tissue obtained as a by-product of therapeutic
temporal lobe resections as described previously (Yong and
Antel, 1992) and in the Materials and methods section. Using
a phagocytosis assay, we then determined that phagocytic
cells constituted an average of 61.9% (F17.3%) of the cells in
the cultures. There were no significant differences in the
phagocytic phenotype between mixed glia cultured in non-
activating medium and those cultured in 0.5%, 1%, 5%, or
10% fetal calf serum (FCS) as measured by the number of
beads ingested per cell (data not shown). Astrocytes and
oligodendrocytes were the other major cell types in the mixed
glial cultures: in three experiments using histochemical
markers, an average of 17.7% of the cells in the cultures
were oligodendrocytes and 3.5% were astrocytes (data not
shown).
Cells maintained for 7–10 days in either nonactivating or
activating medium were infected with R5 HIV isolates that
can infect purified microglia as previously shown (Albright
et al., 1999, 2000b; Strizki et al., 1996). The culture
supernatant was assayed at regular intervals for the produc-
tion of infectious virions using a MAGI assay (Fig. 1A) and
for the presence of p24Gag protein with a standard ELISA
(Fig. 1B). As expected (Gartner et al., 1986; Strizki et al.,
1996; Watkins et al., 1990), infection of the cells maintained
in activating medium was productive, with a rapid rise in
p24Gag concentration (to 10–50 ng/ml) by day 5, and a peak
5–10 days after inoculation (Albright et al., 2000a). In
contrast, infection of cells maintained in nonactivating
medium led to little or no detectable HIV release, or less
than 0.5 ng/ml of p24Gag. We refer to this as a ‘quiescent’
infection. MAGI assay indicated that the differences in viral
production between the cells maintained in nonactivating
Table 1
Components of culture supplements
Fetal calf serum Giant cell tumor supernatant
Albumin (2.8 g/dl) Granulocyte-macrophage colony
stimulating factor (GM-CSF)
Bilirubin (0.2 mg/dl) Granulocyte colony stimulating factor
(G-CSF)
IgG (16.0 mg/dl) Macrophage colony stimulating factor
Insulin ( < 5.0 AIU/ml) Human erythroid enhancing activity
Thyroxine (191.5 nmol/l) Interleukin-1
Testosterone ( < 20.0 ng/dl) Interleukin-6
17-b-Estradiol (2.1 pg/ml) Plasminogen activator, Collagenase,
Prostaglandin E
Fig. 1. Addition of activating medium to HIVDS-br-infected mixed glia
cultured without FCS/GCTS (nonactivating medium) causes reactivation
and release of infectious HIV. Open circles are supernatants from infected
mixed glia cultured in nonactivating medium, open squares are cells that
had activating medium added at day 13 after infection in nonactivating
medium, and black diamonds are from cells maintained in activating
medium throughout. HIV expression is measured in IU/ml (A) or p24gag
(B). HIV reactivation could be seen after mixed glia were infected with HIV
and cultured in nonactivating medium for up to 77 days before the addition
of activating medium (C).
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statistically significant (P < 0.0001; 200 IU/ml was used as
the limit of detection). In paired analysis of 146 samples
from 39 separate experiments, we determined there was an
average of 11.9-fold more infectious virus detected in
activating medium when compared to nonactivating medi-
um (data not shown). Using the more sensitive p24Gag
ELISA, there was a 14.2-fold greater release of p24Gag in
activating medium when compared with nonactivating me-
dium in 17 independent experiments (data not shown). The
similarity of the quantitative results obtained with both
assays ensured that the differences in the patterns ofreplication between the two culture conditions were not
reflective of altered p24Gag/infectious particle ratios or other
potential artifacts.
To determine whether the cells already exposed to HIV
and cultured in nonactivating medium were still capable of
productive viral replication, we added activating medium at
selected time points. The addition of serum components and
cytokines resulted in a rapid increase in viral production to
levels similar to those observed in cells maintained in
activating medium since the time of infection. Figs. 1A
and B indicate that replacement of the nonactivating medi-
um 13 days after infection quickly converted the low-level
infection to a productive infection. To better mirror the long-
lived HIV infection of the CNS that occurs during the entire
life of HIV-infected patient, an experiment was also per-
formed with cells cultured with nonactivating medium for
77 days (Fig. 1C); there was a rapid increase in viral output
after exposing cells to the activating medium.
To ascertain whether a specific pro-inflammatory cyto-
kine (Si et al., 2002) was individually responsible for HIV
reactivation, we analyzed the reactivation response to var-
ious doses of some of the more prominent components of
the FCS and GCTS in the activating medium (Table 1). The
combination of 5% FCS and 5% GCTS consistently resulted
in the highest levels of replication in comparison to non-
activating medium, 5% FCS alone, or 5% GCTS alone (Fig.
2A), which is not surprising in view of the complexity of the
pathways involved in macrophage activation (Winston et al.,
1999). Tumor necrosis factor-a (TNF-a), granulocyte mac-
rophage (GM-CSF), macrophage-(M-CSF), and granulo-
cyte-colony stimulating factors (G-CSF) all resulted in
significant HIV release when compared to nonactivating
medium or control fibroblast growth factor (Fig. 2B). Dose
response curves of G-CSF and M-CSF demonstrated that
the reactivation effect seen in Fig. 2 was consistent and due
to the added factors (data not shown).
Identifying the block to productive HIV infection in resting
mixed glia
HIV can attach to DC-specific intercellular adhesion
molecule-3 grabbing non-integrin (DC-SIGN) on the sur-
face of follicular dendritic cells (FDCs) and survive for long
Fig. 3. Reverse transcription proceeds in cells cultured in nonactivating
medium at levels similar to productive infection (activating medium). Real-
time PCR was performed on DNA samples from various times after
infection using HIV-specific primers and primers specific for GAP-DH, a
cellular housekeeping gene. Levels of proviral genomes are presented as
copies per cell to account for variations due to cell numbers in these
primary cultures. Asterisks (*) indicate significant difference between
nonactivating and activating medium using the nonparametric Mann–
Whitney U test for significance between two data sets. Real-time PCR was
performed on six sets of experimental samples; four using gag primers and
two using ltr-gag primers. Data shown are from one representative
experiment with gag primers. Each data point represents at least four PCR
evaluations.
Fig. 2. Characterization of serum and cytokine components reactivating
HIV in quiescently infected mixed glial cultures. (A) Cultures maintained in
combinations of 0% or 5% FCS/GCTS as noted: 0/0, 5/5, 0/5, 5/0. The
supernatant IU/ml was plotted for days 5 and 9 after infection. The
combination of 5% FCS/GCTS induced a greater viral burst than either 5%
FCS or 5% GCTS alone. (B) Some cytokines individually can reactivate
HIV, but not as well as FCS/GCTS. ‘‘*’’ Indicates that there was
significantly (P < 0.05) more virus as measured by p24gag assay than in the
supernatant of the negative control cultures (nonactivating medium).
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1992), and because microglia expresses DC-SIGN (Shawver
et al., 2000, and Maria Chen unpublished), it was theoret-
ically possible that microglia cultured in nonactivating
medium incorporated HIV into a compartment where the
virus could survive without undergoing reverse transcrip-
tion. Under such circumstances, inhibition of reverse tran-
scription would alter the reactivation of viral replication
when the activating medium was added to quiescently
infected cells. Approximately 1 month after infection, the
nonactivating medium was replaced with either nonactivat-
ing or activating medium, with or without 200 nM efavir-
enz, a non-nucleoside reverse transcriptase inhibitor.
Efavirenz had no effect on HIV reactivation as measured
by release of virus, although it inhibited de novo infection in
previously uninfected glial cultures (data not shown and
Albright et al., 2000a). Experiments with the nucleoside
reverse transcriptase inhibitor AZT, antibodies against
CXCR4 (12G5), CCR5 (2D7), and CD4 (#21), and aCCR5 small molecule inhibitor (TAKEDA 779) also had
no effect on reactivation (data not shown).
These initial results indicated an HIV replication block
after reverse transcription, but it was possible that small
differences at several stages in the replication cycle could
eventually result in inefficient HIV replication. We therefore
performed real-time PCR for gag DNA to quantitatively
detect a major product of reverse transcription and observed
slightly higher levels of gag copies per cell in activating
medium (range 10–30 copies/cell) compared to the levels in
nonactivating medium (0–10 copies/cell) (Fig. 3). Through-
out the entire time course of infection, several of these time
points were significantly different (P < 0.05). Focusing on
early times points (24–48 h postinfection), which is the
estimated average time necessary for one round of replica-
tion transcription in macrophages (Schmidtmayerova et al.,
1998), we observed only a 2- to 3-fold greater gag copies
per cell in activating medium compared to nonactivating
medium. DNAse treatment of viral stocks reduced the signal
due to transfected DNA by 91–95%, making the contribu-
tion of this DNA minimal; therefore, the signal seen at day 0
in the nonactivated cultures may be due to intravirion
reverse transcription within particles adhered to cells. Pre-
vious reports have estimated 103–104 copies of HIV DNA
per 106 resting T lymphocytes (Chun et al., 1997a, 1997b),
which is considerably lower but is not from a uniform
infection (Pierson et al., 2000). With an MOI of 1, we
expect a much higher frequency of infection of microglia in
this system. Cumulative analysis from four separate experi-
ments showed a similar trend (data not shown). Analysis
Fig. 5. HIV transcription occurs in activated and nonactivated cultures.
Quantitative RT-PCR was performed on RNA isolated from activated and
nonactivated mixed glial cultures from four different donors 3–5 days
postinfection. To account for differences in cell number, HIV gag values are
expressed relative to GAP-DH. (Open circles: nonactivated cultures; black
diamonds: activated cultures).
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strated a slight increase in DNA copies per cell (Fig. 3).
PCR primers used to detect a later stage of reverse tran-
scription, second-strand transfer, yielded similar results
(data not shown). Therefore, we concluded that there was
a slight difference in levels of reverse transcripts between
cells in activating and nonactivating medium; however, this
small difference was not able to account for the greater than
10-fold difference seen in virus release (Fig. 1).
We then looked at viral integration into the host cell
genome, a process that has been found to have a predilection
for transcriptionally active sites (Schroder et al., 2002). In
long-lived T cells, post-integration latency has been pro-
posed to be the most clinically relevant form of long-term
latent infection (Cavert and Haase, 1998; Cavert et al., 1997;
Perelson et al., 1997; Pierson et al., 2002). We used Alu–
LTR PCR as previously described (Sonza et al., 1996) in
either nonactivating or activating medium culture conditions
at 1, 2, 3, and 5 days after infection (Fig. 4). Integrated
genomes were detected as early as 1 day postinoculation in
cells from both culture conditions, and through 2, 3, and 5
days postinfection (Fig. 4). To control for the presence of
DNA in each sample, GAPDH was used in concurrent PCR
assays. From these reverse transcription and integration
results, we concluded that HIV integration occurs under
both culture conditions.
Most of the current literature suggests that during
post-integration latency, there is little or no viral tran-
scription and concomitantly no protein expression (Cavert
and Haase, 1998; Cavert et al., 1997). Therefore, we
examined RNA production of a late viral transcript using
quantitative RT-PCR specific for full-length viral RNA.Fig. 4. Mixed glia cultured in nonactivating and activating medium contain integ
specific probe was performed on DNA from HIV-1YU-2-infected mixed glia culture
Integration was detected as early as 1 day (24 h) with signal seen through days 3 a
total DNA in each sample. DNA from uninfected glia from the same experimen
contains some spillover signal. DNA from infected MAGI-CCR5 cells was used as
This figure is representative of a total of five experiments.Taking the level of transcription in the activated cultures
as 100%, in five separate experiments (four donors), viral
RNA was detected at a level of 123.4% (F52.9%) in
nonactivated cultures (Fig. 5). No statistically significant
difference in the relative ratio of gag/GAP-DH between
the two culture conditions was found using ANOVA. We
also performed immunofluorescence assays with antibod-
ies against Gag protein as a test of the degree of gene
expression in the cells maintained in nonactivating me-
dium. Cells that had the morphological appearance ofrated provirus. Alu–LTR PCR and Southern blotting with an HIV-1 LTR
d in nonactivating or activating medium at days 1, 2, 3, and 5 postinfection.
nd 5 in this representative blot. GAP-DH PCR was performed to control for
t, as well as a no template reaction, was used as negative controls, which
a positive control. Signal in the center lane of day 2 represents loading error.
Fig. 7. Western blot performed with an anti-Gag serum demonstrates that
the nonactivated mixed glial cultures have an altered p24gag/p55gag ratio in
comparison with the activated cultures. Treatment with 5 AM saquinivir
confirms that processing of p55gag under either condition is due to a
saquinivir-sensitive protease. This figure is representative of four experi-
ments performed with cells from separate donors.
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di-I-AcLDL (Strizki et al., 1996) were positive for gag
expression using a polyclonal antiserum (Fig. 6), but the
proportion of cells positive for viral antigen was greater
in the cultures maintained in activating medium compared
to cultures in nonactivating medium. At 4–8 days post-
infection, activating medium cultures had on average
35.1% cells that were Gag positive; nonactivating medi-
um cultures had an average of 6.4% Gag-positive cells
(data not shown).
We then performed Western blots with a mouse anti-Gag
(see Materials and methods) on cellular lysates from both
culture conditions to examine p55Gag proteolytic processing.
Surprisingly, using cells from four separate donors, we
found that infected mixed glia in nonactivating culture
conditions displayed a p24/p55 ratio of greater than 1 in
comparison with the activated cultures (Fig. 7), suggesting
premature cleavage of p55Gag under nonactivating condi-
tions. In cells infected under nonactivating conditions then
reactivated, the phenotype reverted to one where the p55
band predominated (data not shown).
It was possible that premature p55Gag proteolytic cleav-
age by a cellular protease was responsible for the defect in
viral output observed in nonactivated cultures. To test this
hypothesis, we infected activated and nonactivated mixed
glia in the presence or absence of 5 AM Saquinivir, a
specific inhibitor of the HIV-1 protease, and confirmed theFig. 6. Immunofluorescence microscopy detects HIV-1 Gag protein in infected
polyclonal antibody against Gag (UP598, a gift from Michael Malim, King’s Colle
in other experiments phagocytosed beads and stained for di-I-AcLDL (both microg
conditions. This figure is representative of a total of six experiments.efficient suppression of p55Gag processing by Western blot
(Fig. 7). HIV-1 gag-specific quantitative RT-PCR also
detected viral RNA in the supernatants from activated
cultures regardless of Saquinivir treatment, but no viral
RNA was detected in the supernatants from nonactivated
infected cultures in the absence or presence of inhibitor.
Therefore, premature p55Gag cleavage is associated with this
quiescent infection, but is not the proximate mechanism
restricting viral production and release. Our data indicate the
existence of a replication block that has no immediatecells cultured in either nonactivating or activating medium using a rabbit
ge London). Mixed glia, which morphologically appear to be microglia and
lial markers), were Gag positive in both activating (A) and nonactivating (C)
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primary cells or in other models of HIV latency.Discussion
Because of their longevity and capacity to harbor lenti-
viral genomes for long periods of time, the microglia, the
principal cell infected in the CNS (Bagasra et al., 1996;
Koenig et al., 1986; Wiley et al., 1986), is a potential HIV
reservoir (Cavert and Haase, 1998; Pierson et al., 2000;
Ryzhova et al., 2002). Not coincidentally, microglia and
brain macrophages are felt to be the key mediator of the
neurologic disease caused by HIV, as they secrete neuro-
toxic products and viral proteins (reviewed in Kaul et al.,
2001). However, the most consistent neuropathological
correlation with HAD is the presence of activated microglia,
as defined by the expression of immunocytochemical acti-
vation markers (Glass et al., 1995; Tyor et al., 1992;
Wesselingh et al., 1993). Our experiments were designed
to mimic the conditions that lead to activation by adding
proteins known to activate microglia and brain macro-
phages. The nonactivating medium conditions represent
the nonactivated state of the normal healthy CNS, while
the activating medium conditions mimic the pathologically
inflamed CNS found during disease and viral infection
(Jordan et al., 1991; Strizki et al., 1996; Watkins et al.,
1990).
Our experiments had three principal goals: (1) identifi-
cation of the stage or stages at which the productive
infection is blocked, (2) narrowing down the factors respon-
sible for activation, and (3) most ambitiously, pinpointing
the cellular pathways and specific molecules involved in the
reactivation of HIV infection and the release of infectious
virus.
Our initial bias was that our system would be similar to
latent infection of T lymphocytes, and we were somewhat
surprised to find that reverse transcription, integration, and
viral transcription proceeded unimpeded, difficult as it is to
quantify the Alu–LTR PCR results. Further investigation
showed significant Gag expression in quiescently infected
microglia, albeit to lower levels than those seen in a fully
productive infection of cells cultured in activating condi-
tions, suggesting that the block to viral production is post-
transcriptional (Fig. 6). Therefore, in contrast to the long-
term latency states in CD4+ T lymphocytes, which are often
due to inefficient initiation of transcription, decreased tran-
script elongation, or failure of export of unspliced viral
mRNA (Butera, 2000), our model so far appears to demon-
strate that HIV transcription and translation are proceeding in
nonactivated cells.
Interestingly, we noted an unusual phenotype of alter-
ation in the processing of p55Gag. The premature processing
was sensitive to inhibition by HIV protease inhibitors and is
therefore unlikely to be due to a cellular protease. Kraus-
slich (1992) reported a similar p24Gag accumulation pheno-type in a transfected Gag/Protease system treated with low
levels of a protease inhibitor, which is much different than
our system. Additionally, we saw neither an increase in total
Gag expression nor increased cytotoxicity in our nonacti-
vated cultures in either the presence or absence of protease
inhibitor (Kaplan and Swanstrom, 1991; Krausslich, 1992).
Our intuitive hypothesis is that a key protein involved in
viral assembly is upregulated or altered in the activated
cultures, and while the altered processing is associated with
this phenomenon, we do not believe it is the immediate
mechanism of inefficient viral production.
We were not surprised that a wide range of cytokines and
serum components made the microglia permissive for rep-
lication and reactivation of HIV (Fig. 2). Many different
cytokines and cytokine receptors are expressed by activated
macrophages, although the full set of molecules in the
activation pathway has not been catalogued (Nau et al.,
2002). Microarray data confirmed that the activating medi-
um results in the robust activation of a specific set of genes,
with significant increases in immune and cell signaling
genes (Albright, unpublished data). Other than NEDD4, a
factor reported to be involved in retrovirus budding or
assembly (Kikonyogo et al., 2001; Strack et al., 2000),
there were no obvious changes in proteins involved in HIV
assembly (data not shown).
In conclusion, while reverse transcription and integration
may be slightly impaired in nonactivating cultures, this
alone cannot account for the greater than 10-fold difference
in virus release between infected cells under the two con-
ditions tested. Recent studies have helped delineate where
and how HIV matures and buds in macrophages (Demirov
et al., 2002; Ono and Freed, 2004; Pelchen-Matthews et al.,
2003; Raposo et al., 2002), and as we continue to investi-
gate the exact posttranslational replication block in our
model, we are focusing on Gag biochemistry, protein
localization, assembly, and budding. Because our model
employs differential cellular activation or expression, future
studies may lead to insights into late stage interactions
between HIV and the host cell, as well as provide new
therapeutic targets for HIV-1 infection.Materials and methods
Isolation and culture of mixed macro- and microglia
We cultured microglia, astrocytes, and oligodendrocytes
together in conditions that mirror those seen in a healthy
CNS and did not favor viral replication (Albright et al.,
2000b) through an adaptation of protocols previously
published (Strizki et al., 1996; Yong and Antel, 1992).
Three to 10 ml of fresh tissue, obtained as a by-product
from individuals undergoing therapeutic surgery for epi-
lepsy, were incubated with 0.25% trypsin and mechanically
dissociated by forcing with a pipette through a cell strainer.
The resulting cells and small debris were diluted in PBS
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premium fetal calf serum (FCS; Atlanta Biologicals, GA)
was not used for inactivation of trypsin. The mix of cells
and debris was centrifuged for 10 min at 1750  g and the
resulting pellet was resuspended in culture medium with
Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 4.5 g/l glucose, 50 mg/ml gentamicin, and
1 mM sodium pyruvate. FCS and giant cell tumor super-
natant (GCTS; IGEN, Gaithersburg, MD), a fixture of this
culture system, were omitted (nonactivating medium) (Ta-
ble 1). The mix of cells and debris was plated directly onto
either 6- or 96-well plates, or 8-well Lab-Tek Permanox
chamber slides (Nalge Nunc International, Naperville, IL,
USA) at a density of 1–2 ml of starting minced tissue per
plate or chamber slide, and cultured in nonactivating
medium. After 4–16 h, cultures were washed and cultured
again in nonactivating medium. To increase yield, a 2nd
plating of cells, not yet adhered to the plastic culture ware,
was performed for an additional 24 h. All cells were then
cultured for several weeks, with daily medium changes
until all debris was gone, and more medium changes every
3–5 days thereafter.
Characterization of cultures
To determine the proportion of microglia in mixed glial
cultures, a carboxyl polystyrene (latex) bead mix (Spher-
otech, Libertyville, IL) was added (1.6, 1.87, 2.17, 2.18,
3.18, 3.54, and 4.1 Am) in appropriate culture medium, with
each bead type having a final concentration of 0.005% w/v.
After incubation at 37 jC for 2–4 h, cells with more than 10
beads inside were considered to be live, functional micro-
glia. Cell types, not of a macrophage lineage, that do not
phagocytose beads were used as negative controls. Percen-
tages of oligodendrocytes and astrocytes in mixed glial
cultures were identified using immunofluorescence as pre-
viously described with antibodies against glial fibrillary
acidic protein (GFAP, Novus) and GalCer (Albright et al.,
1996).
HIV-1 infection of microglia cultured with or without
FCS/GCTS
Microglia were cultured and infected at an approximate
multiplicity of infection of one infectious virus units per
cell, with several CCR5-tropic HIV isolates known to
infect microglia: HIV-1YU-2, HIV-1BaL, and HIV-1DS-br
(Albright et al., 1999; Popovic and Gartner, 1987). All
viral stocks were titered, infectious units per ml (IU/ml),
using an infectious MAGI assay as previously described
(Albright et al., 2000a). The initial experiments were
performed from Ba-L and DS-br viral stocks made in
monocyte-derived macrophages (MDM). To obtain viral
stocks in medium without FCS/GCTS, later experiments
used the cloned HIV-1YU-2 (RF-1), isolated from the brain
of an individual with HIVD (Li et al., 1991) with itsaccessory genes repaired (Fouchier et al., 1997). Virus
stocks were prepared by transfecting 293T cells that had
been growing at log phase for at least 2 days. The cells
were plated at a density of 300,000 or 3  105 cells/well
and cultured in DMEM with 10% FCS after addition of 3
Ag of the pYU-2(RF-1) plasmid for 4–16 h as previously
described (Shieh et al., 1998). After transfection, the 293T
cells were carefully washed and fed with nonactivating
medium. Virus supernatants were collected 24 and 48
h after transfection and centrifuged for 10 min at 3000
rpm to remove cellular debris. Stocks were treated with 20
U/ml DNase for 1 h at 25 jC in 5 mM MgCl2. To infect
microglia, the virus was added and the nonactivating
medium replaced, as indicated, with either standard micro-
glia (activating) medium with 5% FCS (Atlanta Biolog-
icals) and 5% GCTS (Fisher) (Strizki et al., 1996; Watkins
et al., 1990), or nonactivating medium (as described
above). In some experiments, efavirenz, a non-nucleoside
reverse transcriptase inhibitor of HIV-1, was used at 200
nM, a concentration previously determined to be approx-
imately 10 times greater than the in vitro IC90 concentra-
tion in microglia but that was not toxic to these cells
(Albright et al., 2000a).
Virus release assays
Culture supernatants were assayed for the presence of
(1) infectious virus on the indicator cell lines, U373-
MAGI-CCR5 and U373-MAGI-CXCR4, with the parental
U373-MAGI as a negative control cell line (Albright et al.,
2000b; Vodicka et al., 1997); and (2) Viral p24Gag antigen
using the HIV-1 p24Gag ELISA kit according to manufac-
turer’s instructions (Perkin-Elmer, Boston, MA).
Real-time PCR to detect HIV reverse transcription
To obtain DNA samples, cells were lysed in the follow-
ing buffer: 100 mM KCl, 0.1% NP40, 20 mM Tris pH 8.4,
0.5 mg/ml Proteinase K, incubated at 56 jC for 2 h, and
boiled for 15 min to inactivate the Proteinase K. Real-time
PCR was then performed in 96-well plate format (USA
Scientific Inc, #1404-9700) using an ABI Prism 7700
thermocycler and the following reagents: 0.25 mM dNTPs,
5 mM MgCl2, 1 AM primers and probe, 1.25 U Ampli-Taq
Gold. Cycling conditions were as follows: 50 jC for 2 min;
95 jC for 10 min; 40 cycles of 95 jC for 15 s, 60 jC for 1
min. ACH-2 DNA lysates were used to create a standard
curve from which HIV copy number in experimental sam-
ples was calculated and statistically compared using the
nonparametric Mann–Whitney U test for significance be-
tween two data sets. Primer and probe sequences are
available as supplemental information. Gag DNA real-time
PCR analysis utilized the published primers SK38 (nt
1542–1569) and SK39 (nt 1629–1656), and the probe
SK19 (nt 1589–1620). All primers and probes were
obtained from the University of Pennsylvania Center for
A.V. Albright et al. / Virolog336AIDS Research (CFAR). ACH-2 DNAwas used to generate
a standard curve for GAP-DH and data plotted as reverse
transcripts per cell.
Alu–LTR PCR and Southern blotting to detect HIV
integration
DNA samples were obtained as described above. Nested
Alu–LTR PCR was performed with primers at a concentra-
tion of 0.5 AM (Alu) and 3 AM (LTR) for each round, and
the following reagents: 0.2 mM dNTPs, 1.5 mMMgCl2, and
2.5 U Ampli-Taq Gold. Cycling conditions for each round
were 95 jC for 10 min; 40 cycles of 95 jC for 30 s, 50 jC
for 1 min, 72 jC for 1 min 40 s; and 72 jC for 7 min. After
nested PCR, Southern blotting was performed to detect PCR
products as per manufacturers instructions using the
NEL624 Perkin-Elmer 3V-End labeling Biotin Kit with
Streptavidin-AP. HIV-1 probe sequence was YU-2 LTR
(nt 1–40). As a control, GAP-DH DNA was amplified
simultaneously in parallel with the first round Alu–LTR
PCR. Reaction conditions were identical, with 0.5 AM
primer concentrations; all primer sequences are available
as supplemental data.
Cytokines used for HIV reactivation
In the initial HIV reactivation experiments, quiescently
infected microglia was treated with 500 ng/ml of the
following growth factors and cytokines (R&D Systems,
Minneapolis, MN): tumor necrosis factor-a (TNF-a), gran-
ulocyte-macrophage colony stimulating factor (GM-CSF),
granulocyte colony stimulating factor (G-CSF), macro-
phage colony stimulating factor (M-CSF), fibroblast
growth factor (FGF), and interferon-gamma (IFN). For
later dose response curve experiments, the microglia was
treated with 0–50000 U/ml of growth factors or cytokines
calculated using the WHO 1st International Standard Unit
convention that is based on biological activity and R&D
Systems’ conversion factor for each growth factor or
cytokine (available at www.rndsystems.com). Concentra-
tion ranges were based on the reported ED50 for each
growth factor or cytokine.
Statistical analyses
Unless otherwise noted, the Student’s t test was used
for small samples (n < 30). In larger samples (n > 30),
we tested the difference of means using z scores for
normal curve area with the assumption of normality
(Sokal and Rohlf, 1995). A type II error of less than
5% (P < 0.05) was allowed for all tests, unless otherwise
indicated. To calculate 95% confidence interval estimates
for the difference between two populations, we compared
the averages of the two means (nonactivating vs. activat-
ing medium) and the appropriate z scores calculated
(Sternstein, 1994).Quantitative RT-PCR
Total RNA was isolated with Trizol Reagent (Invitrogen,
Carlsbad, CA) 3–5 days postinfection. cDNA was made
using SuperScript First-Strand Synthesis System for RT-
PCR (Invitrogen #11904018) with Oligo (dT) as per man-
ufacturer’s instructions, and then used for real-time PCR
analysis using molecular beacons (see above). Primers
specific for gag and GAP-DH were used (see above), except
for a different GAP-DH reverse primer specific for RNA
sequences. The standard curve for relative GAP-DH values
was based on dilutions of PBMCs from which RNA was
isolated and cDNA synthesized.
Indirect immunofluorescence
Microglia cultured in 8-well Lab Tek chamber slides was
infected and sampled as previously described (Albright et al.,
2000b). Cells were washed twice in PBS, fixed with fresh 4%
paraformaldehyde for 1 h at 37 jC to permeabilize the cell
membrane, and incubated at room temperature with a block-
ing solution consisting of 0.1% BSA and 8% goat serum for
60 min (Albright et al., 2000b). Primary antibody staining
was performed either with UP598, anti-Gag polyclonal rabbit
antiserum (a gift fromM.Malim), or with a pre-immunization
antiserum from the same rabbit. Cells were then stained with
a FITC-conjugated goat anti-rabbit IgG (whole molecule)
(Sigma, #F-0511, St. Louis, MO), washed three times in PBS,
and visualized with a Leitz Aristoplan microscope and I3
Ploemopak Fluorescent vertical illuminator. A 515-nm long
pass suppression filter was used to distinguish FITC-positive
microglia from background autofluorescence, which appears
as a bright yellowish–green color, and is generally confined
to perinuclear patches. The more conventional L3 illumina-
tor, which has a 525/520 nm band pass suppression filter
(Albright et al., 2000b), does not distinguish between FITC
and autofluorescent signals. Photographs were taken with a
Wild Leitz MPS46 Photoautomat camera exposing Kodak
Ektachrome film (ASA400) for 12 s for all images such that
the intensity of staining could be compared among different
photographs.
Western blot analysis of Gag expression
Mixed glial cultures were infected with HIVYU-2 as
described above and cultured in the presence or absence of
5 AM Saquinivir mesylate. Seven days postinfection, cells
were lysed in 0.5% Triton X-100 containing protease inhib-
itors (Complete Inhibitor Cocktail Tablets, Roche). Total
protein concentration was determined using Bio-Rad DC
Protein Assay, and 2 Ag of total protein loaded per well.
After SDS-PAGE and transfer to nitrocellulose, the mem-
brane was blocked in 0.2% Tween 20 in PBS with 5% milk
for 1 h at room temperature, followed by overnight incubation
at 4 jC with mouse monoclonal antibody 24-3 (gift from M.
Malim) that specially recognizes HIV p24gag. A secondary
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containing Gag proteins and visualized using Pierce Super-
Signal chemiluminescent reagents.Acknowledgments
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